ArticleScientific reports2019
Knockout rat models mimicking human atherosclerosis created by Cpf1-mediated gene targeting.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Molecular mechanisms and biotechnology applications of CRISPR-Cas12a.Nature reviews. Molecular cell biology · 2026Review
- Rodent Models for Atherosclerosis.International journal of molecular sciences · 2025Review
- Apolipoprotein E Deficiency Produces an Inflammatory Abdominal Aortic Aneurysm in a Rat Calcium Chloride-Induced Model.The Journal of surgical research · 2025Article
- Research advances in branched-chain amino acid metabolism in tumors.Molecular and cellular biochemistry · 2025Review
- CRISPR-Cpf1 system and its applications in animal genome editing.Molecular genetics and genomics : MGG · 2024Review
- Stable long-term germline transmission of GFP transgenic rat via PiggyBac transposon mediated gene transfer.BMC veterinary research · 2024Article
- Engineering of a high-fidelity Cas12a nuclease variant capable of allele-specific editing.PLoS biology · 2024Article
- Characterization of a novel model for atherosclerosis imaging: the apolipoprotein E-deficient rat.EJNMMI research · 2023Article
- CRISPR applications in cancer diagnosis and treatment.Cellular & molecular biology letters · 2023Review
- Insight into the molecular mechanism of the transposon-encoded type I-F CRISPR-Cas system.Journal, genetic engineering & biotechnology · 2023Review
- Research progress on nucleic acid detection and genome editing of CRISPR/Cas12 system.Molecular biology reports · 2023Review
- Current and Prospective Applications of CRISPR-Cas12a in Pluricellular Organisms.Molecular biotechnology · 2023Review
- Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery.Clinical science (London, England : 1979) · 2022Article
- Non-Mouse Models of Atherosclerosis: Approaches to Exploring the Translational Potential of New Therapies.International journal of molecular sciences · 2022Review
- Mechanics of CRISPR-Cas12a and engineered variants on λ-DNA.Nucleic acids research · 2022Article
- Recent Advances in the Production of Genome-Edited Rats.International journal of molecular sciences · 2022Review
- Circulating gut microbiota-related metabolites influence endothelium plaque lesion formation in ApoE knockout rats.PloS one · 2022Article
- Exosome-eluting stents for vascular healing after ischaemic injury.Nature biomedical engineering · 2021Article
- Advances in Genome Editing and Application to the Generation of Genetically Modified Rat Models.Frontiers in genetics · 2021Review
- The G2A Receptor Deficiency Aggravates Atherosclerosis in Rats by Regulating Macrophages and Lipid Metabolism.Frontiers in physiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rat is a time-honored traditional experimental model animal, but its use is limited due to the difficulty of genetic modification. Although engineered endonucleases enable us to manipulate the rat genome, it is not known whether the newly identified endonuclease Cpf1 system is applicable to rats. Here we report the first application of CRISPR-Cpf1 in rats and investigate whether Apoe knockout rat can be used as an atherosclerosis model. We generated Apoe- and/or Ldlr-deficient rats via CRISPR-Cpf1 system, characterized by high efficiency, successful germline transmission, multiple gene targeting capacity, and minimal off-target effect. The resulting Apoe knockout rats displayed hyperlipidemia and aortic lesions. In partially ligated carotid arteries of rats and mice fed with high-fat diet, in contrast to Apoe knockout mice showing atherosclerotic lesions, Apoe knockout rats showed only adventitial immune infiltrates comprising T lymphocytes and mainly macrophages with no plaque. In addition, adventitial macrophage progenitor cells (AMPCs) were more abundant in Apoe knockout rats than in mice. Our data suggest that the Cpf1 system can target single or multiple genes efficiently and specifically in rats with genetic heritability and that Apoe knockout rats may help understand initial-stage atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.